journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/28753595/clinico-biological-significance-of-suppressor-of-cytokine-signaling-1-expression-in-acute-myeloid-leukemia
#1
H-A Hou, J-W Lu, T-Y Lin, C-H Tsai, W-C Chou, C-C Lin, Y-Y Kuo, C-Y Liu, M-H Tseng, Y-C Chiang, Y-L Peng, J-L Tang, Z Gong, L-I Lin, H-F Tien
Suppressor of cytokine signaling 1 (SOCS1) protein, which encodes a member of signal transducers and activators of transcription-induced inhibitors, takes part in a negative regulation of cytokine signaling. The mechanism of SOCS1 in tumor carcinogenesis is complex and there have been no studies concerning the clinic-biologic implication of SOCS1 expression in acute myeloid leukemia (AML). Here, we first identified that higher bone marrow (BM) SOCS1 expression was closely associated with older age, FLT3-ITD, NPM1 and DNMT3A mutations, but negatively correlated with CEBPA mutation in patients with de novo AML...
July 28, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28753594/the-first-in-class-alkylating-hdac-inhibitor-edo-s101-is-highly-synergistic-with-proteasome-inhibition-against-multiple-myeloma-through-activation-of-multiple-pathways
#2
L Besse, M Kraus, A Besse, J Bader, T Silzle, T Mehrling, C Driessen
No abstract text is available yet for this article.
July 28, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28731459/malignant-t-cells-activate-endothelial-cells-via-il-17%C3%A2-f
#3
B Lauenborg, I V Litvinov, Y Zhou, A Willerslev-Olsen, C M Bonefeld, C Nastasi, S Fredholm, L M Lindahl, D Sasseville, C Geisler, M M Wasik, T Krejsgaard, L M R Gjerdrum, L Iversen, N Odum, A Woetmann
No abstract text is available yet for this article.
July 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28731458/flow-cytometry-based-monocyte-subset-analysis-accurately-distinguishes-chronic-myelomonocytic-leukemia-from-myeloproliferative-neoplasms-with-associated-monocytosis
#4
M M Patnaik, M M Timm, R Vallapureddy, T L Lasho, R P Ketterling, N Gangat, M Shi, A Tefferi, E Solary, K K Reichard, D Jevremovic
No abstract text is available yet for this article.
July 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28731457/mir-155-mir-150-network-regulates-progression-through-the-disease-phases-of-chronic-lymphocytic-leukemia
#5
K Vargova, M Pesta, P Obrtlikova, N Dusilkova, L Minarik, J Vargova, A Berkova, Z Zemanova, K Michalova, M Spacek, M Trneny, T Stopka
No abstract text is available yet for this article.
July 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28731456/upregulation-of-tet-activity-with-ascorbic-acid-induces-epigenetic-modulation-of-lymphoma-cells
#6
N Shenoy, T Bhagat, E Nieves, M Stenson, J Lawson, G S Choudhary, T Habermann, G Nowakowski, R Singh, X Wu, A Verma, T E Witzig
The Ten Eleven Translocation (TET) enzymes have been found to be mutated in both diffuse large B-cell (DLBCL) and peripheral T-cell (PTCL) lymphomas resulting in DNA hypermethylation. Recent studies in embryonal stem cells showed that ascorbic acid (AA) is a cofactor for TET with a binding site at the catalytic domain, and enhances TET activity. We hypothesized that AA could potentially enhance TET activity in lymphoma cells to cause DNA demethylation, reactivate expression of tumor suppressor genes and enhance chemosensitivity...
July 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28708130/clinical-and-prognostic-significance-of-e1a2-bcr-abl1-transcript-subtype-in-chronic-myeloid-leukemia
#7
Z Gong, L J Medeiros, J E Cortes, L Zheng, J D Khoury, W Wang, G Tang, S Loghavi, R Luthra, W Yang, H M Kantarjian, S Hu
No abstract text is available yet for this article.
July 14, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28686226/myc-is-a-positive-regulator-of-choline-metabolism-and-impedes-mitophagy-dependent-necroptosis-in-diffuse-large-b-cell-lymphoma
#8
J Xiong, L Wang, X-C Fei, X-F Jiang, Z Zheng, Y Zhao, C-F Wang, B Li, S-J Chen, A Janin, R P Gale, W-L Zhao
The activation of oncogenes can reprogram tumor cell metabolism. Here, in diffuse large B-cell lymphoma (DLBCL), serum metabolomic analysis revealed that oncogenic MYC could induce aberrant choline metabolism by transcriptionally activating the key enzyme phosphate cytidylyltransferase 1 choline-α (PCYT1A). In B-lymphoma cells, as a consequence of PCYT1A upregulation, MYC impeded lymphoma cells undergo a mitophagy-dependent necroptosis. In DLBCL patients, overexpression of PCYT1A was in parallel with an increase in tumor MYC, as well as a decrease in serum choline metabolite phosphatidylcholine levels and an International Prognostic Index, indicating intermediate-high or high risk...
July 7, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28665419/acute-lymphoblastic-leukemia-a-comprehensive-review-and-2017-update
#9
REVIEW
T Terwilliger, M Abdul-Hay
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per year in the United States alone. The hallmark of ALL is chromosomal abnormalities and genetic alterations involved in differentiation and proliferation of lymphoid precursor cells. In adults, 75% of cases develop from precursors of the B-cell lineage, with the remainder of cases consisting of malignant T-cell precursors. Traditionally, risk stratification has been based on clinical factors such age, white blood cell count and response to chemotherapy; however, the identification of recurrent genetic alterations has helped refine individual prognosis and guide management...
June 30, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28665418/significance-of-the-absolute-lymphocyte-monocyte-ratio-as-a-prognostic-immune-biomarker-in-newly-diagnosed-multiple-myeloma
#10
T Dosani, F Covut, R Beck, J J Driscoll, M de Lima, E Malek
No abstract text is available yet for this article.
June 30, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28665417/vegf-vegfr2-and-gstm1-polymorphisms-in-outcome-of-multiple-myeloma-patients-treated-with-thalidomide-based-regimens
#11
L Lopes-Aguiar, M T Delamain, A B C Brito, G J Lourenço, E F D Costa, G B Oliveira, J Vassallo, C A De Souza, C S P Lima
No abstract text is available yet for this article.
June 30, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28665416/a-gene-expression-signature-distinguishes-innate-response-and-resistance-to-proteasome-inhibitors-in-multiple-myeloma
#12
A K Mitra, T Harding, U K Mukherjee, J S Jang, Y Li, R HongZheng, J Jen, P Sonneveld, S Kumar, W M Kuehl, V Rajkumar, B Van Ness
Extensive interindividual variation in response to chemotherapy is a major stumbling block in achieving desirable efficacy in the treatment of cancers, including multiple myeloma (MM). In this study, our goal was to develop a gene expression signature that predicts response specific to proteasome inhibitor (PI) treatment in MM. Using a well-characterized panel of human myeloma cell lines (HMCLs) representing the biological and genetic heterogeneity of MM, we created an in vitro chemosensitivity profile in response to treatment with the four PIs bortezomib, carfilzomib, ixazomib and oprozomib as single agents...
June 30, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28665415/cryptic-t-3-8-q27-q24-and-or-myc-bcl6-linkage-associated-with-myc-expression-by-immunohistochemistry-is-frequent-in-multiple-hit-b-cell-lymphomas
#13
H Ohno, M Nakagawa, C Kishimori, K Fukutsuka, G Honjo
No abstract text is available yet for this article.
June 30, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28649984/cd27-expression-and-its-association-with-clinical-outcome-in-children-and-adults-with-pro-b-acute-lymphoblastic-leukemia
#14
D Chen, N Gerasimčik, A Camponeschi, Y Tan, Q Wu, S Brynjolfsson, J Zheng, J Abrahamsson, J Nordlund, G Lönnerholm, L Fogelstrand, I-L Mårtensson
No abstract text is available yet for this article.
June 23, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28649983/high-rate-of-event-free-survival-at-24-months-with-everolimus-rchop-for-untreated-diffuse-large-b-cell-lymphoma-updated-results-from-ncctg-n1085-alliance
#15
T E Witzig, B LaPlant, T M Habermann, E McPhail, D J Inwards, I N Micallef, J P Colgan, G S Nowakowski, S M Ansell, P B Johnston
No abstract text is available yet for this article.
June 23, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622306/changes-in-uninvolved-immunoglobulins-during-induction-therapy-for-newly-diagnosed-multiple-myeloma
#16
P Ravi, S Kumar, W Gonsalves, F Buadi, M Q Lacy, R S Go, A Dispenzieri, P Kapoor, J A Lust, D Dingli, Y Lin, S J Russell, N Leung, M A Gertz, R A Kyle, P L Bergsagel, S V Rajkumar
Little is known about the impact of multiple myeloma (MM) treatment on uninvolved immunoglobulins (Ig). We identified 448 patients who received high-dose dexamethasone (HD-DEX), lenalidomide and dexamethasone (RD), bortezomib and dexamethasone (VD), bortezomib, cyclophosphamide and dexamethasone (VCD) or bortezomib, lenalidomide and dexamethasone (VRD) for newly diagnosed MM at our institution between 2000 and 2013, and who had available data on absolute lymphocyte count (ALC) and quantitative uninvolved Ig at baseline and at the end of four cycles of therapy...
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622305/the-thrombopoietin-mpl-axis-is-activated-in-the-gata1-low-mouse-model-of-myelofibrosis-and-is-associated-with-a-defective-rps14-signature
#17
M Zingariello, L Sancillo, F Martelli, F Ciaffoni, M Marra, L Varricchio, R A Rana, C Zhao, J D Crispino, A R Migliaccio
Myelofibrosis (MF) is characterized by hyperactivation of thrombopoietin (TPO) signaling, which induces a RPS14 deficiency that de-regulates GATA1 in megakaryocytes by hampering its mRNA translation. As mice carrying the hypomorphic Gata1(low) mutation, which reduces the levels of Gata1 mRNA in megakaryocytes, develop MF, we investigated whether the TPO axis is hyperactive in this model. Gata1(low) mice contained two times more Tpo mRNA in liver and TPO in plasma than wild-type littermates. Furthermore, Gata1(low) LSKs expressed levels of Mpl mRNA (five times greater than normal) and protein (two times lower than normal) similar to those expressed by LSKs from TPO-treated wild-type mice...
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622304/outcomes-of-newly-diagnosed-myeloma-patients-requiring-dialysis-renal-recovery-importance-of-rapid-response-and-survival-benefit
#18
M A Dimopoulos, M Roussou, M Gavriatopoulou, D Fotiou, D C Ziogas, M Migkou, I Panagiotidis, E Eleutherakis-Papaiakovou, N Kanellias, E Psimenou, S Marinaki, D Bacharaki, D Mparmparoussi, C Matsouka, S Giannouli, E Terpos, E Kastritis
No abstract text is available yet for this article.
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622303/addition-of-cyclophosphamide-and-higher-doses-of-dexamethasone-do-not-improve-outcomes-of-patients-with-al-amyloidosis-treated-with-bortezomib
#19
E Kastritis, M Gavriatopoulou, M Roussou, D Fotiou, D C Ziogas, M Migkou, E Eleutherakis-Papaiakovou, I Panagiotidis, N Kanellias, E Psimenou, E Papadopoulou, C Pamboucas, E Manios, H Gakiopoulou, A Ntalianis, A Tasidou, S Giannouli, E Terpos, M A Dimopoulos
Bortezomib, in combination with dexamethasone (VD) or with the addition of cyclophosphamide (VCD), is highly effective in patients with amyloid light-chain (AL) amyloidosis. Currently, VCD is considered as a primary regimen for patients with AL, but it is not clear whether the addition of cyclophosphamide to VD further and significantly improves efficacy, given the substantial activity of bortezomib itself. We retrospectively compared the outcomes of 101 patients with AL amyloidosis who received VD (n=59) or VCD (n=42) in two consecutive periods...
June 16, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28622302/evaluation-of-coagulopathy-before-and-during-induction-chemotherapy-for-acute-lymphoblastic-leukaemia-including-assessment-of-global-clotting-tests
#20
K Burley, J Salem, T Phillips, C Reilly-Stitt, D I Marks, O Tunstall, J Moppett, A Mumford, C A Bradbury
No abstract text is available yet for this article.
June 16, 2017: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"